Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Healing & Recovery Stack

Peptide Schedule Research Team

+

The gold standard healing combination. BPC-157 handles local tissue repair — tendons, ligaments, gut lining — while TB-500 works systemically to reduce inflammation and promote cell migration throughout the body.

A 2025 systematic review by Vasireddi's group (PMID 40756949) screened 544 papers on BPC-157. Thirty-six met inclusion criteria. Thirty-five were preclinical studies. One was clinical. That ratio says a lot about where the science stands right now. The review's orthopaedic search ran through June 3, 2024, and kept studies of mechanism, musculoskeletal outcomes, metabolism and safety. FDA's July 2026 briefing searched every use and counted five small human studies, two known only from meeting abstracts.

The BPC-157 peptide (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) from a protective protein in human gastric juice. In animal and cell studies, it promotes tissue repair through angiogenesis (VEGF-driven blood vessel growth), nitric oxide modulation, and FAK-paxillin pathway activation in tendon cells. One property separates it from most peptides: it stays stable in human gastric juice (PMID 38675421). In rats, oral dosing works for gut injuries; no human study has measured how much of an oral dose is absorbed.

Animal data is reproducible across labs and species. Healing acceleration has been confirmed in tendons, ligaments, muscles, nerves, corneas, and intestinal ulcers. A 2024 intravesical case series (12 patients (n=12) with interstitial cystitis) reported 80 to 100 percent symptom resolution. A 2025 IV pilot by Lee and Burgess confirmed tolerability up to 20 mg intravenous in two adults.

Community data adds a different kind of evidence. Across r/Peptides, ExcelMale, and Longecity, users have reported steady outcomes for years. Pain reduction and improved mobility within 1 to 3 weeks for soft tissue injuries. Gut symptom relief within days on oral dosing. Faster post-surgical recovery. The community figured out the standard protocol before the researchers caught up. 250 mcg subcutaneous twice daily, near the injury, for 4 to 6 weeks.

BPC-157 has no FDA approval. The FDA placed it on the Category 2 bulk drug substance list in 2023, blocking compounding. Its nominators withdrew it, and FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. FDA's Pharmacy Compounding Advisory Committee (PCAC) discussed BPC-157 on July 23, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today.

Compared to TB-500, BPC-157 targets local tissue repair near the injection site through angiogenesis and NO modulation. TB-500 works systemically regardless of injection location. The two are commonly paired in a 1:1 ratio for combined local and systemic coverage.

LevelDose / InjectionFrequency
Beginner250 mcg2x Daily
Moderate500 mcgDaily
Aggressive500 mcg2x Daily

Seven amino acids. That is all TB-500 is. Acetylated leucine-lysine-lysine-threonine-glutamate-threonine-glutamine, pulled from positions 17 through 23 of the 43-amino-acid thymosin beta-4 protein. CAS number 885340-08-9, molecular weight 889.0 Da.

The mechanism is well characterized in animals. TB-500 binds monomeric G-actin, sequestering free actin subunits and remodeling the cytoskeleton so that endothelial and immune cells migrate faster to damaged tissue. It upregulates VEGF 2.5 to 3.8-fold. Malinda and colleagues confirmed that thymosin beta-4 increased reepithelialization by 42% at day 4 and 61% at day 7 versus controls in rat full-thickness skin wounds (PMID 10469335). It also suppresses myofibroblast differentiation, which reduces scar formation.

What makes TB-500 unusual is systemic distribution. You don't need to inject near the injury. Subcutaneous injection in the abdomen reaches a torn rotator cuff the same way it reaches a strained hamstring. Community users have validated this property thousands of times over.

No published study has given the TB-500 fragment to people. FDA's briefing for the July 2026 compounding advisory committee meeting found no clinical studies or human exposure data for it by any route. A 2024 metabolite study by Rahaman and colleagues added a wrinkle: the parent compound showed no wound-healing activity in vitro. The metabolite Ac-LKKTE was the active species. That finding has not changed community dosing practices, but it raises questions about mechanism attribution.

Community confidence (4.1/5 sentiment, 500+ r/Peptides threads) sits well ahead of the formal evidence base. TB-500 was on the FDA Category 2 list from 2024 until its nominators withdrew it; FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. PCAC discussed it on July 23, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today. All current supply is unregulated gray-market product.

LevelDose / InjectionFrequency
Beginner2 mg2x/week
Moderate2.5 mg2x/week
Aggressive5 mg2x/week

Interactions

BPC-157 + TB-500Synergistic

Gold standard healing stack. BPC-157 handles local tissue repair while TB-500 works systemically. Different mechanisms, highly complementary.

Check these 2 in the interaction checker

Protocol Tips

  • BPC-157 works best injected near the injury site when possible.
  • TB-500 is systemic — injection location does not matter.
  • Run for 4-6 weeks, then assess. Many see results within 2 weeks.
  • Consider the pre-mixed BPC-157 + TB-500 blend for convenience.

Related Guides & Comparisons

Beginner-tier doses from each peptide's page load into a preview you can change.

Open the calculator for BPC-157
Explore all Healing & Recovery peptides